BioSpace News Archive

Drug Development

Takeda’s Epilepsy Drug Stumbles in Back-to-Back Phase III Rare Disease Failures

Takeda’s soticlestat, licensed from Ovid Therapeutics, did not significantly reduce seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome, respectively, according to two late-stage readouts on Monday.

June 17, 2024
·
2 min read
·
Tristan Manalac
FDA

AstraZeneca’s Imfinzi Gets FDA Approval for Treating Endometrial Cancer

AstraZeneca on Monday secured FDA approval for its blockbuster Imfinzi, in combination with chemotherapy, to treat adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.

June 17, 2024
·
2 min read
·
Tyler Patchen
Drug Development

FDA Slaps BioNTech-MediLink ADC With Partial Clinical Hold Due to ‘Significant Risk of Illness’

The hold on BioNTech and MediLink’s antibody-drug conjugate candidate BNT326/YL202 has halted enrollment in a Phase I U.S. trial in patients with non-small cell lung cancer or breast cancer, following multiple deaths.

June 17, 2024
·
1 min read
·
Kate Goodwin
Policy

BioSpace at #DIA2024: Convergence and Collaboration

BioSpace’s ⁠Lori Ellis⁠ and ⁠Chantal Dresner⁠ bring live updates from ⁠the first day of #DIA2024⁠ in San Diego.

June 17, 2024
·
1 min read